BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
33510545
Number of visits today
940
Number of downloads
16697273
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Abou Assi R, Abdulbaqi IM, Siok Yee C. The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. Pharmaceuticals (Basel) 2021;14:215. [PMID: 33806527 DOI: 10.3390/ph14030215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Sahu T, Pande B, Pl M, Verma HK. Liver dysfunction during COVID-19 pandemic: Contributing role of associated factors in disease progression and severity. World J Hepatol 2022;14:1099-110. [PMID: 35978661 DOI: 10.4254/wjh.v14.i6.1099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Rui F, Yang H, Hu X, Xue Q, Xu Y, Shi J, Li J. Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management. Infectious Microbes and Diseases 2022;4:49-55. [DOI: 10.1097/im9.0000000000000089] [Reference Citation Analysis]
3 Kolaric TO, Nincevic V, Kuna L, Duspara K, Bojanic K, Vukadin S, Raguz-Lucic N, Wu GY, Smolic M. Drug-induced Fatty Liver Disease: Pathogenesis and Treatment. J Clin Transl Hepatol 2021;9:731-7. [PMID: 34722188 DOI: 10.14218/JCTH.2020.00091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345